Skip to main content
Erschienen in: Digestive Diseases and Sciences 10/2021

21.10.2020 | Original Article

Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants

verfasst von: Ahmad M. Al-Taee, Elie Ghoulam, Preston Lee, Mitchell Edwards, Kahee A. Mohammed, Christine Y. Hachem

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Peptic ulcer disease (PUD) develops in approximately 25% of chronic users of non-steroidal anti-inflammatory drugs (NSAIDs). The incidence of uncomplicated PUD has been declining over the past 3 decades unlike that of complicated PUD in the elderly. An expert consensus document published jointly in 2008 by the American College of Gastroenterology (ACG), the American College of Cardiology Foundation (ACCF), and the American Heart Association (AHA) provided recommendations on prevention of PUD among users of antiplatelets and anticoagulants. This work aimed to evaluate physicians’ compliance with these guidelines in a tertiary academic setting.

Methods

We examined our medical record database for the 9 month period extending from April 2018 until December 2018. Using this database, we identified elderly patients (> 64 years old) who were chronic (> 3 months) users of low dose aspirin (81 mg once daily) and had an indication for PUD prophylaxis as per the ACG–ACCF–AHA guideline document. We performed a retrospective chart review of patients included in this study. Descriptive statistics were compared using χ2 and independent sample t tests.

Results

A total of 852 patients were included in this study. The mean age was 75 years old, and 43% of patients were females. In addition to aspirin, patients were prescribed P2Y12 inhibitors (45.5%), direct oral anticoagulants (DOACs) (23%), warfarin (12%), steroids (9%) or enoxaparin (1%). Users of DOACs were most commonly prescribed apixaban (16%), followed by rivaroxaban (6%) and dabigatran (1%). Overall, only 40% of patients with an indication for PUD prophylaxis received a proton pump inhibitor.

Conclusion

PUD prophylaxis may be underutilized in elderly patients. This finding, along with increasing rates of NSAID use and an aging population, may help explain the increased incidence of complicated PUD in the elderly. Efforts are needed to raise physician awareness of PUD prophylaxis guidelines.
Literatur
1.
Zurück zum Zitat Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74:1237–1244.PubMedCrossRef Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74:1237–1244.PubMedCrossRef
2.
Zurück zum Zitat Dregan A, et al. Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol. 2018;28:440–446.PubMedCrossRef Dregan A, et al. Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol. 2018;28:440–446.PubMedCrossRef
3.
Zurück zum Zitat Abraham NS, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323–332.PubMedCrossRef Abraham NS, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323–332.PubMedCrossRef
4.
Zurück zum Zitat Piper JM, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.PubMedCrossRef Piper JM, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.PubMedCrossRef
5.
Zurück zum Zitat Enestvedt BK, et al. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc. 2008;67:422–429.PubMedCrossRef Enestvedt BK, et al. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc. 2008;67:422–429.PubMedCrossRef
6.
Zurück zum Zitat Hunt RH, et al. Critical issues in the pathophysiology and management of peptic ulcer disease. Eur J Gastroenterol Hepatol. 1995;7:685–699.PubMed Hunt RH, et al. Critical issues in the pathophysiology and management of peptic ulcer disease. Eur J Gastroenterol Hepatol. 1995;7:685–699.PubMed
8.
Zurück zum Zitat Cai S, et al. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;30:1039–1048.PubMedCrossRef Cai S, et al. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;30:1039–1048.PubMedCrossRef
9.
Zurück zum Zitat Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9:45–51.PubMed Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9:45–51.PubMed
10.
Zurück zum Zitat Primatesta P, Goldacre MJ, Seagroatt V. Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol. 1994;23:1206–1217.PubMedCrossRef Primatesta P, Goldacre MJ, Seagroatt V. Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol. 1994;23:1206–1217.PubMedCrossRef
11.
Zurück zum Zitat Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–464.PubMedPubMedCentralCrossRef Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–464.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Kang JY, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002. Aliment Pharmacol Ther. 2006;24:65–79.PubMedCrossRef Kang JY, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002. Aliment Pharmacol Ther. 2006;24:65–79.PubMedCrossRef
13.
Zurück zum Zitat Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996;6:489–504.PubMedCrossRef Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996;6:489–504.PubMedCrossRef
14.
Zurück zum Zitat Bombardier C, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343:1520–1528.PubMedCrossRef Bombardier C, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343:1520–1528.PubMedCrossRef
15.
Zurück zum Zitat Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247–1255.PubMedCrossRef Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247–1255.PubMedCrossRef
16.
Zurück zum Zitat Griffin MR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257–263.PubMedCrossRef Griffin MR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257–263.PubMedCrossRef
17.
Zurück zum Zitat Shorr RI, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665–1670.PubMedCrossRef Shorr RI, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665–1670.PubMedCrossRef
18.
Zurück zum Zitat Targownik LE, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–944.PubMedCrossRef Targownik LE, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–944.PubMedCrossRef
19.
Zurück zum Zitat Lanza FL, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989;84:633–636.PubMed Lanza FL, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989;84:633–636.PubMed
20.
Zurück zum Zitat Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med. 1998;338:719–726.PubMedCrossRef Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med. 1998;338:719–726.PubMedCrossRef
21.
Zurück zum Zitat Hawkey CJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med. 1998;338:727–734.PubMedCrossRef Hawkey CJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med. 1998;338:727–734.PubMedCrossRef
22.
Zurück zum Zitat Moayyedi P, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157:403–412.PubMedCrossRef Moayyedi P, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157:403–412.PubMedCrossRef
23.
Zurück zum Zitat Koch M, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321–2332.PubMedCrossRef Koch M, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321–2332.PubMedCrossRef
24.
Zurück zum Zitat Graham DY, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169–175.PubMedCrossRef Graham DY, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169–175.PubMedCrossRef
25.
Zurück zum Zitat Rostom A, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:2296. Rostom A, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:2296.
26.
Zurück zum Zitat Leontiadis GI, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:1–164.CrossRef Leontiadis GI, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:1–164.CrossRef
27.
Zurück zum Zitat Bhatt DL, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008;52:1502–1517.PubMedCrossRef Bhatt DL, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008;52:1502–1517.PubMedCrossRef
28.
Zurück zum Zitat Lanza FL, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738.PubMed Lanza FL, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738.PubMed
29.
Zurück zum Zitat Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28:420–425.PubMedCrossRef Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28:420–425.PubMedCrossRef
30.
Zurück zum Zitat Gomm W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.PubMedCrossRef Gomm W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.PubMedCrossRef
32.
Zurück zum Zitat Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813.PubMedPubMedCentralCrossRef Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48.PubMedCrossRef Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48.PubMedCrossRef
34.
Zurück zum Zitat Bundhun PK, et al. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty? A systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord. 2017;17:3.PubMedPubMedCentralCrossRef Bundhun PK, et al. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty? A systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord. 2017;17:3.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Focks JJ, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart. 2013;99:520–527.PubMedCrossRef Focks JJ, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart. 2013;99:520–527.PubMedCrossRef
36.
Zurück zum Zitat Chen J, et al. Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo—a systematic review. Clin Cardiol. 2013;36:184–189.PubMedPubMedCentralCrossRef Chen J, et al. Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo—a systematic review. Clin Cardiol. 2013;36:184–189.PubMedPubMedCentralCrossRef
37.
38.
Zurück zum Zitat Gargiulo G, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study trial. Am Heart J. 2016;174:95–102.PubMedCrossRef Gargiulo G, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study trial. Am Heart J. 2016;174:95–102.PubMedCrossRef
39.
Zurück zum Zitat Vaduganathan M, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129:1002–1005.PubMedCrossRef Vaduganathan M, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129:1002–1005.PubMedCrossRef
40.
Zurück zum Zitat Aadland E, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 1987;83:37–40.PubMedCrossRef Aadland E, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 1987;83:37–40.PubMedCrossRef
41.
Zurück zum Zitat Raskin JB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–350.PubMedCrossRef Raskin JB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–350.PubMedCrossRef
Metadaten
Titel
Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants
verfasst von
Ahmad M. Al-Taee
Elie Ghoulam
Preston Lee
Mitchell Edwards
Kahee A. Mohammed
Christine Y. Hachem
Publikationsdatum
21.10.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06665-w

Weitere Artikel der Ausgabe 10/2021

Digestive Diseases and Sciences 10/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.